We are providing the early breast cancer patients with faster and more precise risk stratification as we can predict a relapse from sera earlier than clinically available methods. We do compute a prognostic and predictive model, integrating microRNAs with other biomarkers.

We are Futuretics, on the mission to bring molecularly personalized solutions to the patients.